EUVIMEDEUVIMED entdecken
Crossref

Factors Associated With Underutilization of Antiviral Therapy in Preventing Hepatitis B Virus‐Related Hepatocellular Carcinoma

Jia-Ling Wu, Ying-Nan Tsai iD, Cheng-Hao Tseng iD, Shang-Chen Tseng, Chih-Wen Lin iD, Chih-Lung Hung, Mindie H Nguyen iD, Jaw-Town Lin, Yao-Chun Hsu iD

Alimentary Pharmacology & Therapeutics · 2025

DOI: 10.1111/apt.70224 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Alimentary Pharmacology & Therapeutics, 2025. Verfasst von Jia-Ling Wu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Public Health, National Cheng Kung University, College of Medicine, Tainan, Taiwan. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Antiviral Agents, Liver Neoplasms, Hepatitis B. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 27 Literaturangaben. Gefördert von: E-Da Hospital, Gilead Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Deaths from hepatitis B virus (HBV)‐related hepatocellular carcinoma (HCC) are projected to increase through 2030. Underutilisation of antiviral therapy may contribute to this concerning trend but empirical data remain sparse.

Aims

We aimed to assess the frequency of missed opportunities for antiviral therapy before HBV‐related HCC development and to investigate factors associated with non‐treatment.

Methods

We analysed the electronic medical records from a large healthcare group in Taiwan to identify all HBV‐infected patients who developed HCC between 1 April 2004 and 24 May 2022. HBV infection was confirmed by hepatitis B surface antigen seropositivity and incident HCC was verified through the cancer registry. Patients were grouped based on whether they had received antiviral therapy prior to the HCC diagnosis.

Results

Among 1017 patients with HBV‐related HCC (median age, 60.8 years; 80.1% male; 42.9% with cirrhosis), 75% had not received antiviral therapy before developing HCC. Compared to treated patients, the untreated group had a significantly lower proportion of cirrhosis (33.5% vs. 71.0%), higher platelet counts, elevated liver enzyme levels, and higher viral loads. They also had significantly fewer specialist visits (median frequency, 0.3 vs. 3.6 visits per year) and biomarker evaluations, and were less frequently diagnosed at early stages (Stage I/II, 49.5% vs. 81.6%) with a significantly shorter median survival (2.1 vs. 4.4 years).

Conclusion

Three‐quarters of patients who developed HBV‐related HCC had not received antiviral therapy before HCC diagnosis. These patients were characterised by a lower proportion of cirrhosis, infrequent clinical visits, fewer HBV evaluations, more advanced HCC stage, and poorer prognosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularAntiviral AgentsLiver NeoplasmsHepatitis BHepatitis B, ChronicHumansMaleFemaleMiddle AgedAgedTaiwanAdultHepatitis B virusLiver Cirrhosis

Stichwörter der Autor:innen

antiviral agentshealthcare underutilizationhepatitis B virushepatocellular carcinoma

Substanzen

Antiviral Agents

Autor:innen und Institutionen

  • Department of Public Health, National Cheng Kung University, College of Medicine, Tainan, Taiwan.
  • School of Medicine, College of Medicine, I-Shou University, Kaohsiung, Taiwan.
  • Division of Gastroenterology and Hepatology, E-Da Cancer Hospital, I-Shou University, Kaohsiung, Taiwan.
  • Division of Gastroenterology and Hepatology, E-Da Hospital, I-Shou University, Kaohsiung, Taiwan.
  • Administrative Center, E-Da Healthcare System, Kaohsiung, Taiwan.
  • Division of Gastroenterology and Hepatology, Stanford University Medical Center, Palo Alto, California, USA.

ORCID-Profile: Ying-Nan Tsai, Cheng-Hao Tseng, Chih-Wen Lin, Mindie H Nguyen, Yao-Chun Hsu

Förderung

  • E-Da Hospital
  • Gilead Sciences

Zitieren

APA

Wu, J. L., Tsai, Y. N., Tseng, C. H., Tseng, S. C., Lin, C. W., Hung, C. L., Nguyen, M. H., Lin, J. T., & Hsu, Y. C. (2025). Factors Associated With Underutilization of Antiviral Therapy in Preventing Hepatitis B Virus‐Related Hepatocellular Carcinoma. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.70224

Vancouver

Wu JL, Tsai YN, Tseng CH, Tseng SC, Lin CW, Hung CL, et al. Factors Associated With Underutilization of Antiviral Therapy in Preventing Hepatitis B Virus‐Related Hepatocellular Carcinoma. Alimentary Pharmacology & Therapeutics. 2025. doi:10.1111/apt.70224

BibTeX
@article{Wu2025,
  author = {Wu, Jia-Ling and Tsai, Ying-Nan and Tseng, Cheng-Hao and Tseng, Shang-Chen and Lin, Chih-Wen and Hung, Chih-Lung and Nguyen, Mindie H and Lin, Jaw-Town and Hsu, Yao-Chun},
  title = {Factors Associated With Underutilization of Antiviral Therapy in Preventing Hepatitis B Virus‐Related Hepatocellular Carcinoma},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2025},
  doi = {10.1111/apt.70224}
}
Infokarte | EUVIMED

Artikeldaten derzeit nicht verfügbar.

Recherche